Compare Adaptive Biotechnologies Corp (ADPT) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lucid Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.11 (market cap $4.04B), while Lucid Group Inc trades at $6.47 (market cap $2.64B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | LCID | |
|---|---|---|
Market Cap | $4.04B | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $24.77 |
52-Week Low | $12.30 | $4.62 |
Enterprise Value | $4.10B | $5.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Lucid Group (LCID) trades at $6.47, down 2.12% on the day, reflecting ongoing investor concerns over persistent losses and cash burn. The stock exhibits a bearish technical trend with key support at $6, while fundamentally, the company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by a -249.21% net income margin. Recent news highlights an operational reset aiming for $1.4 billion in cash savings and a delayed midsize EV launch to 2027.
The outlook remains challenging with significant execution risks, though a $10.50 analyst price target suggests potential upside if cost-cutting and new initiatives like robotaxi partnerships succeed. High cash burn and competitive pressures pose substantial risks to near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
